Grant: Alliance Grants
Université de Montréal
$66,667.00
Development of single-cell sequencing based method for mAb identification and validation_x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
The overall goal of this project is to develop more cost-effective methods for generating monoclonal antibodies (mAb) against cancer biomarkers. While the traditional protocols for mAb generation used by companies such as MédiMabs have been established decades ago, recent technological developments have opened the door to new and potentially far more efficient methodologies. In this project, we will research the use of single cell DNA sequencing as a method to rapidly identify mAb producing cells without performing traditional hybridoma fusions. In order to do this, we will perform single cell RNA sequencing on B-cells from mice that have been immunized with an antigen of interest. When these cells are prepared for sequencing, the same antigen is added, however this version of the antigen also has a DNA barcode attached. When B cells that can recognize the antigen bind it, the attached DNA barcode is also added to the single cell sequencing reaction. This allows the simultaneous sequencing of both the barcode (if present) and the region encoding the antibody that can recognize the antigen. With this sequence information available, any antibodies of interest can be cloned into a new stable cell line for efficient production. At the same time, we will assess various approaches to optimize this part of the process, including rapid expression and translation of sequenced clones to allow their functional validation. These experiments will be done in the context of several biomarkers that have been identified in a subgroup of pediatric acute myeloid leukemia (AML) identified by the Wilhelm lab. Because of the numerous potential advantages of this approach with respect to time and cost of mAb production, there is both a strong scientific as well as economic value underpinning the proposed work.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
558390-2020
Name nom
Wilhelm, Brian
Department département
Institut de recherche en immunologie et en cancérologie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
66667
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of single-cell sequencing based method for mAb identification and validation_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
The overall goal of this project is to develop more cost-effective methods for generating monoclonal antibodies (mAb) against cancer biomarkers. While the traditional protocols for mAb generation used by companies such as MédiMabs have been established decades ago, recent technological developments have opened the door to new and potentially far more efficient methodologies. In this project, we will research the use of single cell DNA sequencing as a method to rapidly identify mAb producing cells without performing traditional hybridoma fusions. In order to do this, we will perform single cell RNA sequencing on B-cells from mice that have been immunized with an antigen of interest. When these cells are prepared for sequencing, the same antigen is added, however this version of the antigen also has a DNA barcode attached. When B cells that can recognize the antigen bind it, the attached DNA barcode is also added to the single cell sequencing reaction. This allows the simultaneous sequencing of both the barcode (if present) and the region encoding the antibody that can recognize the antigen. With this sequence information available, any antibodies of interest can be cloned into a new stable cell line for efficient production. At the same time, we will assess various approaches to optimize this part of the process, including rapid expression and translation of sequenced clones to allow their functional validation. These experiments will be done in the context of several biomarkers that have been identified in a subgroup of pediatric acute myeloid leukemia (AML) identified by the Wilhelm lab. Because of the numerous potential advantages of this approach with respect to time and cost of mAb production, there is both a strong scientific as well as economic value underpinning the proposed work.